Compare TWO & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWO | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.4M |
| IPO Year | 2009 | N/A |
| Metric | TWO | DRUG |
|---|---|---|
| Price | $13.52 | $80.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $12.31 | ★ $106.75 |
| AVG Volume (30 Days) | ★ 3.4M | 262.0K |
| Earning Date | 02-02-2026 | 02-13-2026 |
| Dividend Yield | ★ 9.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $532,207,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 498.21 | N/A |
| 52 Week Low | $9.30 | $23.18 |
| 52 Week High | $14.28 | $123.75 |
| Indicator | TWO | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 69.01 | 45.56 |
| Support Level | $13.12 | $81.72 |
| Resistance Level | $13.83 | $87.58 |
| Average True Range (ATR) | 0.59 | 4.13 |
| MACD | 0.04 | -1.41 |
| Stochastic Oscillator | 77.41 | 12.38 |
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.